JP2015516370A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015516370A5 JP2015516370A5 JP2014560445A JP2014560445A JP2015516370A5 JP 2015516370 A5 JP2015516370 A5 JP 2015516370A5 JP 2014560445 A JP2014560445 A JP 2014560445A JP 2014560445 A JP2014560445 A JP 2014560445A JP 2015516370 A5 JP2015516370 A5 JP 2015516370A5
- Authority
- JP
- Japan
- Prior art keywords
- lrg1
- antagonist
- tumor
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000005557 antagonist Substances 0.000 claims description 82
- 102000018918 Activin Receptors Human genes 0.000 claims description 36
- 108010052946 Activin Receptors Proteins 0.000 claims description 36
- 210000004881 tumor cell Anatomy 0.000 claims description 32
- 206010028980 Neoplasm Diseases 0.000 claims description 30
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 claims description 18
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 16
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims description 14
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims description 14
- 229940112869 bone morphogenetic protein Drugs 0.000 claims description 14
- 230000003828 downregulation Effects 0.000 claims description 14
- 108010036395 Endoglin Proteins 0.000 claims description 12
- 102100037241 Endoglin Human genes 0.000 claims description 12
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 12
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 12
- 230000003993 interaction Effects 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 8
- 230000011664 signaling Effects 0.000 claims description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 108010033276 Peptide Fragments Proteins 0.000 claims description 6
- 102000007079 Peptide Fragments Human genes 0.000 claims description 6
- 108091005735 TGF-beta receptors Proteins 0.000 claims description 6
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 claims description 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 230000003915 cell function Effects 0.000 claims description 6
- 230000014509 gene expression Effects 0.000 claims description 6
- 210000002865 immune cell Anatomy 0.000 claims description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 5
- 230000001772 anti-angiogenic effect Effects 0.000 claims description 5
- 230000000903 blocking effect Effects 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 101000783723 Homo sapiens Leucine-rich alpha-2-glycoprotein Proteins 0.000 claims description 4
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 claims description 4
- 102100035987 Leucine-rich alpha-2-glycoprotein Human genes 0.000 claims description 4
- 108700011259 MicroRNAs Proteins 0.000 claims description 4
- 102100035194 Placenta growth factor Human genes 0.000 claims description 4
- 102100034136 Serine/threonine-protein kinase receptor R3 Human genes 0.000 claims description 4
- 101710082813 Serine/threonine-protein kinase receptor R3 Proteins 0.000 claims description 4
- 108020004459 Small interfering RNA Proteins 0.000 claims description 4
- 102100033663 Transforming growth factor beta receptor type 3 Human genes 0.000 claims description 4
- 230000000259 anti-tumor effect Effects 0.000 claims description 4
- 108010079292 betaglycan Proteins 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 230000012292 cell migration Effects 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000007613 environmental effect Effects 0.000 claims description 4
- 230000012010 growth Effects 0.000 claims description 4
- 230000008611 intercellular interaction Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000002679 microRNA Substances 0.000 claims description 4
- 230000001613 neoplastic effect Effects 0.000 claims description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 4
- 239000004055 small Interfering RNA Substances 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 108020005544 Antisense RNA Proteins 0.000 claims description 3
- 108091023037 Aptamer Proteins 0.000 claims description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 3
- 239000003184 complementary RNA Substances 0.000 claims description 3
- 230000006870 function Effects 0.000 claims description 3
- 102000009840 Angiopoietins Human genes 0.000 claims description 2
- 108010009906 Angiopoietins Proteins 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 229940123869 CD160 antagonist Drugs 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010061968 Gastric neoplasm Diseases 0.000 claims description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 2
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 2
- 206010029098 Neoplasm skin Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 108091008778 RORγ2 Proteins 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 230000002730 additional effect Effects 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 230000001093 anti-cancer Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 230000004663 cell proliferation Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 238000000185 intracerebroventricular administration Methods 0.000 claims description 2
- 238000007917 intracranial administration Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000037841 lung tumor Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000023958 prostate neoplasm Diseases 0.000 claims description 2
- 210000000278 spinal cord Anatomy 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 210000005167 vascular cell Anatomy 0.000 claims description 2
- 230000006444 vascular growth Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 28
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000025189 neoplasm of testis Diseases 0.000 claims 1
- 239000002831 pharmacologic agent Substances 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 claims 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 208000025440 neoplasm of neck Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261608872P | 2012-03-09 | 2012-03-09 | |
| US61/608,872 | 2012-03-09 | ||
| PCT/GB2013/050580 WO2013132267A1 (en) | 2012-03-09 | 2013-03-08 | Treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015516370A JP2015516370A (ja) | 2015-06-11 |
| JP2015516370A5 true JP2015516370A5 (enExample) | 2016-03-17 |
| JP6181088B2 JP6181088B2 (ja) | 2017-08-16 |
Family
ID=47884403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014560445A Expired - Fee Related JP6181088B2 (ja) | 2012-03-09 | 2013-03-08 | 癌の治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20150132226A1 (enExample) |
| EP (1) | EP2822573B1 (enExample) |
| JP (1) | JP6181088B2 (enExample) |
| CA (1) | CA2866696A1 (enExample) |
| ES (1) | ES2647568T3 (enExample) |
| WO (1) | WO2013132267A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6294118B2 (ja) * | 2014-03-25 | 2018-03-14 | 三菱ケミカル株式会社 | 大腸癌マーカー及び大腸癌検出方法 |
| JP6675605B2 (ja) * | 2014-10-10 | 2020-04-01 | 国立大学法人高知大学 | 細胞遊走調節に関する疾患の予防・治療剤および肺間質の疾患の疾患活動性判定・予後評価 |
| EP3243077B1 (en) | 2015-01-05 | 2019-09-04 | University Of Oslo | Prostate cancer markers and uses thereof |
| GB201503438D0 (en) * | 2015-02-27 | 2015-04-15 | Ucl Business Plc | Antibodies |
| US20180042998A1 (en) * | 2015-03-10 | 2018-02-15 | University Of Massachusetts | Targeting gdf6 and bmp signaling for anti-melanoma therapy |
| CN105106973B (zh) * | 2015-09-21 | 2018-08-07 | 广西医科大学 | 肿瘤血管特异性趋化ctl纳米系统及其制备与应用 |
| WO2017139564A1 (en) * | 2016-02-11 | 2017-08-17 | The Johns Hopkins University | Compositions and methods for targeting activin signaling to treat cancer |
| KR102001870B1 (ko) * | 2016-11-03 | 2019-07-19 | 엘지전자 주식회사 | 냉장고 및 이의 제어방법 |
| GB201702792D0 (en) | 2017-02-21 | 2017-04-05 | Queens Univ Of Belfast | A new biomarker for preeclampsia |
| KR102610314B1 (ko) * | 2023-01-27 | 2023-12-06 | 경북대학교 산학협력단 | Lrg1 단백질 또는 이를 코딩하는 유전자를 포함하는 간질환 진단용 바이오마커 조성물 및 치료용 약학 조성물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
| US5503978A (en) | 1990-06-11 | 1996-04-02 | University Research Corporation | Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase |
| US5654151A (en) | 1990-06-11 | 1997-08-05 | Nexstar Pharmaceuticals, Inc. | High affinity HIV Nucleocapsid nucleic acid ligands |
| WO1996038579A1 (en) | 1995-06-02 | 1996-12-05 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to growth factors |
| WO2005027733A2 (en) | 2003-09-18 | 2005-03-31 | Ppd Biomarker Discovery Sciences, Llc | Biological markers for diagnosing multiple sclerosis |
| US7416850B2 (en) | 2006-01-25 | 2008-08-26 | Jemmerson Ronald R | Cytochrome c and leucine-rich alpha-2-glycoprotein-1 assays, methods and antibodies |
| WO2008092214A1 (en) | 2007-02-02 | 2008-08-07 | Minomic International Limited | Biomarkers for diabetes |
| EP2462164A2 (en) * | 2009-08-04 | 2012-06-13 | Biosystems International SAS | Lung cancer biomarkers |
| GB0915515D0 (en) * | 2009-09-04 | 2009-10-07 | Ucl Business Plc | Treatment of vasculoproliferative conditions |
-
2013
- 2013-03-08 WO PCT/GB2013/050580 patent/WO2013132267A1/en not_active Ceased
- 2013-03-08 ES ES13709521.2T patent/ES2647568T3/es active Active
- 2013-03-08 JP JP2014560445A patent/JP6181088B2/ja not_active Expired - Fee Related
- 2013-03-08 US US14/383,887 patent/US20150132226A1/en not_active Abandoned
- 2013-03-08 EP EP13709521.2A patent/EP2822573B1/en active Active
- 2013-03-08 CA CA2866696A patent/CA2866696A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015516370A5 (enExample) | ||
| Mashreghi et al. | Angiogenesis biomarkers and their targeting ligands as potential targets for tumor angiogenesis | |
| Ishii et al. | Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy | |
| Rutkowska et al. | EGFRvIII: an oncogene with ambiguous role | |
| Kienast et al. | Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy | |
| Aurisicchio et al. | The promise of anti-ErbB3 monoclonals as new cancer therapeutics | |
| Zhang et al. | HER3/ErbB3, an emerging cancer therapeutic target | |
| US9605043B2 (en) | Fusion protein for suppressing cancer cell growth and suppressing vasculogenesis, and anticancer composition comprising same | |
| Okroj et al. | Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors | |
| Patel et al. | Targeting the EGFR-family for therapy: biological challenges and clinical perspective | |
| Guo et al. | Engineering the first chimeric antibody in targeting intracellular PRL-3 oncoprotein for cancer therapy in mice | |
| Wang et al. | Platelets involved tumor cell EMT during circulation: communications and interventions | |
| Asano et al. | Anti-HER3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal adenocarcinoma | |
| JP2013503621A5 (enExample) | ||
| Singh et al. | Combined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade | |
| JP2017101068A5 (enExample) | ||
| Belleudi et al. | Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells | |
| Kawakami et al. | HER3 and its ligand, heregulin, as targets for cancer therapy | |
| Liu et al. | The siRNA cocktail targeting VEGF and HER2 inhibition on the proliferation and induced apoptosis of gastric cancer cell | |
| Sala et al. | EV20, a novel anti-ErbB-3 humanized antibody, promotes ErbB-3 down-regulation and inhibits tumor growth in vivo | |
| Prabhu et al. | KAI1/CD82, metastasis suppressor gene as a therapeutic target for non-small-cell lung carcinoma | |
| Tucker et al. | Revisiting the tenascins: exploitable as cancer targets? | |
| Lowery et al. | Growth factor signaling in metastasis: current understanding and future opportunities | |
| de Souza et al. | Membrane microparticles: shedding new light into cancer cell communication | |
| US20160237158A1 (en) | Methods and Compositions for Targeting Tumor Microenvironment and for preventing Metastasis |